Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Tokyo
Clinical trial register · Japan

Clinical Trials in Tokyo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Chūōku 37 Fukuoka 33 Bunkyō City 20 Chiba 19 Nagoya 19
Narrow the registerReset
Recruitment status
Phase
Site location
Chūōku37 Fukuoka33 Bunkyō City20 Chiba19 Nagoya19
All 194 locations
Target enrolment
to

Trials with a site in Tokyo

16 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Chiba, Okayama, Tokyo
2026-05-28
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
Chiba, Okayama, Tokyo
2026-04-17
Recruiting
Eli Lilly and Company
Phase 3
1,980
Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo
2026-02-06
Recruiting
Eli Lilly and Company
Phase 2
222
Shinagawa-ku, Shinjuku, Tokyo
2025-11-03
Recruiting
Eli Lilly and Company
Phase 3
3,400
Bunkyō City, Tokyo
2025-08-25
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 1
240
Kyoto, Tokyo
2025-07-28
Active, closed
Eli Lilly and Company
Phase 3
600
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Eli Lilly and Company
Phase 1
750
Chiba, Kyoto, Shizuoka, Tokyo
2024-10-21
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
Chiba, Kanagawa, Nagoya, Osaka, Tokyo
2024-09-12
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 1
575
Shizuoka, Tokyo
2024-05-20
Recruiting
Eli Lilly and Company
Phase 1
677
Chiba, Nagoya, Tokyo
2023-01-12
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company
Phase 3
150
Bunkyō, Bunkyō City, Kashiwa, Kobe, Tokyo, Yokohama
2021-05-26
Active, closed
Eli Lilly and Company
Phase 3
312
Kagoshima, Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Shinjuku-ku, Tokyo
2020-11-25
Active, closed
Eli Lilly and Company
Phase 3
533
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku, Tokyo
2018-03-14
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/tokyo

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Tokyo that also match the filters currently applied.

How many clinical trials are recruiting in Tokyo?

9 of the 16 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tokyo), 16 studies
PhaseStudiesRecruitingShare
Phase 38350%
Phase 17543.8%
Phase 2116.3%

Most active sponsors

Lead sponsors with the most studies (Tokyo)
Lead sponsorStudiesRecruiting
Eli Lilly and Company169
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.